In advanced tumors, mice treated with vvDD-IL-23 developed long-lasting systemic anti-tumor immunity, significantly increasing CD4+ and CD8+ T cells in tumors, whereas Treg cells were unaffected (133). The gene discussed is IL23A; the disease is neoplasm.